In this paper we demonstrate the ability of anti-ErbB3 antibodies to sensitize cells resistant to EGFR TKIs to these drugs both in an established lung cancer cell line and in primary cultures from malignant pleural effusions of lung adenocarcinoma patients, and that this effect correlates with the expression levels of ErbB3. This evidence concerns the gene EGFR and lung carcinoma.